Status:
COMPLETED
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20-64 years
Phase:
PHASE2
Brief Summary
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM)...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- T2DM diagnosed at least 3 months prior to Screening and fasting plasma glucose (FPG) level \<280mg/dL at the Screening visit.
- Concurrent T2DM therapy: Must be diet controlled - OR - not taking more than 2 oral anti-diabetic agents, and willing to withdraw from these treatments 2 weeks prior to the first dosing.
- Exclusion criteria:
- Must not have any other major illness other than diabetes
Exclusion
Key Trial Info
Start Date :
March 22 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00372957
Start Date
March 22 2006
End Date
June 28 2006
Last Update
September 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site